Viatris, formed from Mylan and Pfizer's Established Brands, has faced stock price volatility since its inception in 2020. I rated Viatris a "Buy" last October, based on management's completion of ...
Viatris is an American pharmaceutical company formed as a result of the merger of Mylan and Upjohn. Over the past two and a half months, Viatris' share price has risen by more than 38%. Viatris' ...
"We are proud of these recent regulatory achievements, which culminate a year of significant R&D advancement in 2025," said Viatris Chief R&D Officer Philippe Martin. "These important milestones not ...
Hosted on MSN
Viatris’s (NASDAQ:VTRS) Q3 Sales Top Estimates
Medication company Viatris (NASDAQ:VTRS) in Q3 CY2025, but sales were flat year on year at $3.76 billion. The company’s full-year revenue guidance of $14.1 billion at the midpoint came in 1.2% above ...
PITTSBURGH, Feb. 27, 2025 /PRNewswire/ -- Viatris Inc. (NASDAQ: VTRS) today announced that on February 24, 2025, its Board of Directors approved a 2025 dividend policy of 48 cents ($0.48) per share ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results